Esophageal Cancer Drugs Market
- 2026 年市場規模
- USD 4.78 Bn
- 2033 年預估規模
- USD 6.78 Bn
- 年複合成長率 CAGR
- 6.7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramucirumab), and Immunotherapy (Pembrolizumab)), By Disease Indication (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Esophageal cancer occurs in the cells that line the inside of the esophagus. Major symptoms include difficulty in swallowing (dysphagia), unintentional weight loss, chest pain, worsening indigestion or heartburn, coughing or hoarseness. Drugs approved by the Food and Drug Administration (FDA) such as Docetaxel, Trifluridine, and Tipiracil Hydrochloride are extensively used chemotherapy for treatment of esophageal cancer. Immunotherapy drug named Pembrolizumab is also used for the treatment of esophageal cancer. In 2017, FDA granted accelerated approval to pembrolizumab (Keytruda) for patients suffering from recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma.
Market Dynamics
Increasing prevalence of esophageal cancer worldwide is expected to boost esophageal cancer drugs market growth. According to World Cancer Research Fund (WCRF) International 2018, esophageal cancer is the seventh most commonly occurring cancer in men and the 13th most commonly occurring cancer in women. There were over 500,000 new cases in 2018, globally. Moreover, geriatric population is at high risk of developing esophageal cancer and men are more vulnerable to developing esophageal cancer. For instance, according to a data published in American Society of Clinical Oncology (ASCO) in 2018, it is estimated that people between the ages of 45 and 70 have the highest risk of esophageal cancer.
However, no drug therapy has been used to cure esophageal cancer completely and the survival rates of esophageal cancer patient significantly decreases after 5 years of treatment. The esophageal cancer drugs do not have any reliability after 5 years of treatment, which is expected to hamper growth of the esophageal cancer drugs market. For instance, according to the study published in the ASCO in January 2019, the 5-year survival rate of people with esophageal cancer is 19%.
Key features of the study
• This report provides in-depth analysis of the esophageal cancer drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global esophageal cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech, Inc., Sanofi-Aventis, and Merck & Co.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global esophageal cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
Market Segmentation
• By Therapy Type
o Chemotherapy
o Docetaxel
o Irinotecan
o Trifluridine
o Tipiracil
o Carboplatin and Paclitaxel
o Cisplatin
o 5-fluorouracil
o Cisplatin with Capecitabine
o Targeted Drug Therapy
o Trastuzumab
o Ramucirumab)
o Immunotherapy (Pembrolizumab)
• By Disease Indication
o Adenocarcinomas
o Gastrointestinal Stromal Tumors
o Carcinoid Tumors
o Squamous Cell Carcinoma
o Others
• By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• By Regional Insights
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Amgen Inc.
o Eli Lilly and Company
o Hoffmann-La Roche
o Bristol-Myers Squibb Company
o Boehringer Ingelheim GmbH
o Bristol-Myers Squibb
o GlaxoSmithKline Plc.
o Novartis AG
o Johnson & Johnson
o Gilead Sciences
o Genentech, Inc.
o Sanofi-Aventis
o Merck & Co.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Therapy Type
Market Snippet, By Disease Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
PEST Analysis
PORTER’s Five Forces Analysis
Market Opportunities
Regulatory Scenario
Key Developments
Industry Trend
4. Global Esophageal Cancer Drugs Market, By Therapy Type, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Chemotherapy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Docetaxel
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Irinotecan
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Trifluridine and Tipiraci
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Carboplatin and Paclitaxel
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Cisplatin and 5-fluorouracil
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Cisplatin with Capecitabine
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Targeted Drug Therapy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Trastuzumab
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Ramucirumab
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Immunotherapy (Pembrolizumab)
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
5. Global Esophageal Cancer Drugs Market, By Disease Indication, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Adenocarcinomas
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Gastrointestinal Stromal Tumors
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Carcinoid Tumors
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Squamous Cell Carcinoma
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
6. Global Esophageal Cancer Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Hospital Pharmacy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Retail Pharmacy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
o Online Pharmacy
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 – 2033
Segment Trends
7. Global Esophageal Cancer Drugs Market, By Region, 2026-2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2021 - 2033
o North America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o Brazil
o Argentina
o Mexico
o Rest of Latin America
o Europe
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
Market Size and Forecast, By Disease Indication, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o South Africa
o North Africa
o Central Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
Amgen Inc.
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Eli Lilly and Company
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
F. Hoffmann-La Roche
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Bristol-Myers Squibb Company
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Boehringer Ingelheim GmbH
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Bristol-Myers Squibb
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
GlaxoSmithKline Plc.
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Novartis AG
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Johnson & Johnson
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Gilead Sciences
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Genentech, Inc.
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Sanofi-Aventis
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
Merck & Co
o Company Overview
o Product Type Portfolio
o Recent Developments/Updates
9. Analyst Recommendation
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
10. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們